MAVMET trial: maraviroc and/or metformin for metabolic dysfunction-associated fatty liver disease(MAFLD) in adults with suppressed HIV.
Journal article
Mccabe L. et al, (2024), AIDS (London, England)
Large-scale phenotyping of patients with long COVID post-hospitalization reveals mechanistic subtypes of disease
Journal article
Liew F. et al, (2024), Nature Immunology, 25, 607 - 621
Long-term efficacy and safety of a treatment strategy for HIV infection using protease inhibitor monotherapy: 8-year routine clinical care follow-up from a randomised, controlled, open-label pragmatic trial (PIVOT).
Journal article
Paton NI. et al, (2024), EClinicalMedicine, 69
Anomalies in the review process and interpretation of the evidence in the NICE guideline for chronic fatigue syndrome and myalgic encephalomyelitis.
Journal article
White P. et al, (2023), Journal of neurology, neurosurgery, and psychiatry
Understanding the treatment benefit of hyperimmune anti-influenza intravenous immunoglobulin (Flu-IVIG) for severe human influenza
Journal article
Vanderven HA. et al, (2023), JCI Insight
Accelerating clinical development of a live attenuated vaccine against Salmonella Paratyphi A (VASP): study protocol for an observer-participant-blind randomised control trial of a novel oral vaccine using a human challenge model of Salmonella Paratyphi A infection in healthy adult volunteers.
Journal article
McCann N. et al, (2023), BMJ Open, 13
Alternative pathway dysregulation in tissues drives sustained complement activation and predicts outcome across the disease course in COVID-19.
Journal article
Siggins MK. et al, (2023), Immunology, 168, 473 - 492
The P323L substitution in the SARS-CoV-2 polymerase (NSP12) confers a selective advantage during infection.
Journal article
Goldswain H. et al, (2023), Genome biology, 24
Malaria patient spectrum representation in therapeutic clinical trials of uncomplicated malaria: a scoping review of the literature.
Journal article
Arena L. et al, (2023), Malaria journal, 22
SARS-CoV-2-specific nasal IgA wanes 9 months after hospitalisation with COVID-19 and is not induced by subsequent vaccination
Journal article
Liew F. et al, (2023), eBioMedicine, 87, 104402 - 104402
Viral Coinfections in Hospitalized Coronavirus Disease 2019 Patients Recruited to the International Severe Acute Respiratory and Emerging Infections Consortium WHO Clinical Characterisation Protocol UK Study.
Journal article
Vink E. et al, (2022), Open forum infectious diseases, 9
Human leukocyte antigen alleles associate with COVID-19 vaccine immunogenicity and risk of breakthrough infection
Journal article
Mentzer AJ. et al, (2022), Nature Medicine
Constructing custom-made radiotranscriptomic signatures of vascular inflammation from routine CT angiograms: a prospective outcomes validation study in COVID-19
Journal article
Kotanidis CP. et al, (2022), The Lancet Digital Health, 4, e705 - e716
Fitting to the UK COVID-19 outbreak, short-term forecasts and estimating the reproductive number
Journal article
Keeling MJ. et al, (2022), Statistical Methods in Medical Research, 31, 1716 - 1737
Impact of cardiometabolic multimorbidity and ethnicity on cardiovascular/renal complications in patients with COVID-19
Journal article
Norris T. et al, (2022), Heart, 108, 1200 - 1208
Mucosal-Associated Invariant T cells exhibit distinct functional signatures associated with protection against typhoid fever
Journal article
Salerno-Gonçalves R. et al, (2022), Cellular Immunology, 378
Distinct clinical symptom patterns in patients hospitalised with COVID-19 in an analysis of 59,011 patients in the ISARIC-4C study.
Journal article
Millar JE. et al, (2022), Scientific reports, 12
Implementation of corticosteroids in treatment of COVID-19 in the ISARIC WHO Clinical Characterisation Protocol UK: prospective, cohort study.
Journal article
Närhi F. et al, (2022), The Lancet. Digital health, 4, e220 - e234
A blood atlas of COVID-19 defines hallmarks of disease severity and specificity
Journal article
Ahern DJ. et al, (2022), Cell, 185, 916 - 938.e58
Namilumab or infliximab compared with standard of care in hospitalised patients with COVID-19 (CATALYST): a randomised, multicentre, multi-arm, multistage, open-label, adaptive, phase 2, proof-of-concept trial
Journal article
Fisher BA. et al, (2022), The Lancet Respiratory Medicine, 10, 255 - 266